

1 **Title: STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in**
2 **Refractory Chronic Rhinosinusitis**

3 **Running title:** STAT4 predicts success in CRS surgery

4

5 Michael R. Abidin M.D.¹, Oral Alpan M.D.² Matthew Plassmeyer PhD², Lina Kozhaya³, Denise
6 Loizou RN², Mikail Dogan, M.D.³, Zachary Upchurch M.D.¹, Nathan P Manes PhD⁴, Aleksandra
7 Nita-Lazar, PhD⁴, Derya Unutmaz, M.D.³, Søren Ulrik Sønder PhD²

8

9 ¹Metropolitan ENT, 6355 Walker Ln, Alexandria, VA-22310, USA

10 ²Amerimmune LLC, 8260 Greensboro Dr VA-22102 McLean, USA

11 ³The Jackson Laboratory, Farmington, CT, 06032 USA

12 ⁴Functional Cellular Networks Section, Laboratory of Immune System Biology, NIAID, NIH,
13 USA

14

15 ORCID

16 Michael R. Abidin M.D.¹ 0000-0001-5679-6667

17 Oral Alpan M.D.² 0000-0001-7467-8541

18 Matthew Plassmeyer PhD² 0000-0001-8068-2125

19 Lina Kozhaya³ 0000-0002-1559-2278

20 Denise Loizou RN²

21 Zachary Upchurch M.D 0009-0001-1357-5765

22 Nathan P Manes PhD⁴ 0000-0001-6701-3314

23 Aleksandra Nita-Lazar PhD⁴ 0000-0002-8523-605X

24 Mikail Dogan M.D.³ 0000-0001-8725-9151

25 Derya Unutmaz, M.D.³ 0000-0001-8898-6633

26 Søren Ulrik Sønder PhD² 0000-0002-4697-8421

27 Corresponding Author: Søren Ulrik Sønder,
28 ssonder@amerimmune.com
29 571-308-1900

30

31 Previous publication: This paper is uploaded to Medrxiv

32 Keywords: Chronic Refractory Sinusitis, CRS, flow cytometry, T-cells, CD4, STAT4,
33 phosphorylation, Cohort study

34 **Conflict of interest:** The Author(s) declare(s) that there is no conflict of interest.

35 **Contributions:**

36 Michael R. Abidin: Design, Conduct, Analysis

37 Oral Alpan: Design, Conduct, Analysis

38 Matthew Plassmeyer: Conduct, Analysis

39 Lina Kozhaya: Conduct, Analysis

40 Denise Loizou: Conduct

41 Zachary Upchurch: Conduct

42 Nathan P Manes: Conduct, Analysis

43 Aleksandra Nita-Lazar: Design

44 Mikail Dogan: Conduct, Analysis

45 Derya Unutmaz: Design, Analysis

46 Søren Ulrik Sønder: Design, Conduct, Analysis

47

48 Funding source: This study was supported by Amerimmune. This study was supported in part by

49 the Intramural Research Program of NIAID, NIH and internal funds to D.U. at Jackson

50 Laboratory.

51 **Abstract:**

52 Objective: Chronic rhinosinusitis (CRS) impacts an estimated 5% to 15% of people worldwide,
53 incurring significant economic healthcare burden. There is a urgent need for the discovery of
54 predictive biomarkers to improve treatment strategies and outcomes for CRS patients.

55 Study design: Cohort study of CRS patients and healthy controls using blood samples.

56 Setting: Out-patient clinics.

57 Methods: Whole blood samples were collected for flow cytometric analysis. Mechanistic studies
58 involved the transfection of human primary T cells and Jurkat cells.

59 Results: Our analysis began with a 63-69 year-old female patient diagnosed with refractory
60 CRS,. Despite undergoing multiple surgeries, she continually faced sinus infections. Whole
61 exome sequencing pinpointed a heterozygous IL-12Rb1 mutation situated in the linker region
62 adjacent to the cytokine binding domain. When subjected to IL-12 stimulation, the patient's CD4
63 T-cells exhibited diminished STAT4 phosphorylation. However, computer modeling or T-cell
64 lines harboring the same IL-12 receptor mutation did not corroborate the hypothesis that IL-
65 12Rb could be responsible for the reduced phosphorylation of STAT4 by IL-12 stimulation.

66 Upon expanding our investigation to a broader CRS patient group using the pSTAT4 assay, we
67 discerned a subset of refractory CRS patients with abnormally low STAT4 phosphorylation.

68 The deficiency showed improvement both in-vitro and in-vivo after exposure to *Latilactobacillus*
69 *sakei* (aka *Lactobacillus sakei*), an effect at least partially dependent on IL-12.

70 Conclusion: In refractory CRS patients, an identified STAT4 defect correlates with poor clinical
71 outcomes after sinus surgery, which can be therapeutically targeted by *Latilactobacillus sakei*
72 treatment. Prospective double-blind placebo-controlled trials are needed to validate our findings.

73

74

75 **Introduction**

76 The intricate web of cellular interactions and cytokine signaling pathways plays a pivotal role in
77 orchestrating the immune response to pathogens. Central to this network is the IL-12/IFN- γ axis,
78 a well-recognized T-helper 1 (Th1) pathway in mediating protective immunity against
79 intracellular pathogens [1]. Interleukin-12 (IL-12), produced predominantly by antigen-
80 presenting cells like dendritic cells and macrophages [2], induces the production of interferon-
81 gamma (IFN- γ) from natural killer cells and T lymphocytes [3,4]. IFN- γ , in turn, acts to
82 stimulate the innate and adaptive arms of the immune system, promoting cellular immunity and
83 controlling pathogen proliferation. IL12R β 1 is a subunit of both the IL-12 and IL-23 receptor
84 complex and binds to the p40 subunit of IL-12 and IL-23. Upon infection with intracellular
85 bacteria, phagocytes are activated and secrete cytokines including IL-12, a signature cytokine for
86 Th1 responses. Following binding of IL-12 to its receptor, STAT4 is phosphorylated which is
87 essential for IFN γ production[1,5,6].

88

89 Disruption of this axis could compromise the ability of the immune system to handle microbial
90 challenges, leading to persistent infections and prolonged inflammation. Indeed, a balanced IL-
91 12/IFN- γ response is essential to clear pathogens, maintain mucosal homeostasis, and prevent
92 tissue damage in the sinuses[1]. Furthermore, recurrent infections, which denote a failure of the
93 immune system to provide lasting protection after initial exposure to a pathogen, may also be
94 linked to perturbations in the IL-12/IFN- γ pathway. An impaired or inadequate IL-12-driven
95 IFN- γ response may not only decrease resistance to primary infections but might also reduce
96 immune memory, rendering individuals more susceptible to recurrent bouts of infections despite

97 adequate surgical intervention [1,7–13]. Although T-cell defects are the most common immune
98 disorder in chronic rhinosinusitis (CRS), clinical workup towards its identification is rarely
99 performed.

100

101 Various dietary supplements have been demonstrated to enhance Th1 responses. Among them
102 included are various lactobacillus probiotic supplements. Although the role of lactobacillus
103 containing supplements, taken orally or topically, is unproven in patients with CRS, small sized
104 studies and anecdotal reports did find correlations with clinical outcomes in the surgical healing
105 process [14–20]. Data from preliminary studies have shown mixed results in patients receiving
106 probiotics containing lactobacilli species. Lactobacilli have the potential of inducing IL-12 from
107 macrophages [21–23].

108

109 Our investigation began with a case of refractory chronic rhinosinusitis (RCRS) associated with
110 a heterozygous IL-12 receptor mutation. Despite observing decreased STAT4 phosphorylation in
111 response to IL-12 stimulation in both the patient and her children, the mutation itself was not
112 proven to be the cause. Further research revealed this decreased phosphorylation to be a common
113 characteristic in a broader RCRS patient cohort. Insights into the IL-12/IFN- γ signaling
114 pathway's role in CRS may unveil new therapeutic targets to enhance immunity, alleviate
115 chronic inflammation, and decrease recurrent infections.

116

117 **Materials and Methods:**

118 **Patients and ethical statement.**

119 The studies involving human participants were reviewed and approved by Western Institutional
120 Review Board (WIRB) Protocol #1285028. Written, informed consent was obtained from the
121 individuals for the publication of any potentially identifiable images or data included in this
122 article. Individuals undergoing steroid or MoAB treatments targeting the IL-12 pathway were
123 excluded from the study. The grouping of CRS and RCRS patient was done according to
124 published guidelines[24,25].

125 Lactobacilli supplements and administration: *Lactobasillus sakei* proBio65 as a nasal rinse 1/4th
126 teaspoon of Lanto Health powder (240 mg) in 2 tablespoons of normal saline nasal rinses once a
127 day and 240 mg twice a day in food.

128 Genetics: Whole Exome Sequencing was carried out by GeneDX (Gaithersburg, MD).

129 Subsequently Sanger sequencing was carried out by MacroGen (Rockville, MD).

130

131 **Flow cytometry and cell culture.**

132 Staining for IL-12R β 1 expression was performed using antibodies against IL-12R β 1, CD4,
133 CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The
134 percentages of CD4 T-cells capable of producing IFN γ (Th1 cells) and IL-17 (Th17 cells) were
135 measured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1 μ g/ml) in the
136 presence of brefeldin A for 4 hours. The cells were then permeabilized and stained with
137 antibodies against CD3, CD4, CD8, CD45RA, CCR6, IFN γ -APC and IL17-PE (BD Bioscience,
138 San Jose, CA). Acquisition was set to 30000 CD3⁺ events. The Th1 mediated IFN γ response was
139 studied by incubating the PBMC for 72 hours in the presents of IL-2 (100 U/ml), IL-12 (100
140 ng/ml), IL-18 (50 ng/ml), and Dynabeads Human T-Activator CD3/CD28 (10 μ l/ml). The cells
141 were then fixed, permeabilized and stained with antibodies against CD3, CD45RO, CD4, IFN γ

142 and fixable viability dye 780. Acquisition was set to 20000 CD4⁺ events. The CAP and CLIA
143 validated pSTAT4 stimulation assays were carried out using whole blood stimulated with IL-12
144 (100ng/ml) for various timepoints, followed by staining with antibodies against CD3, CD4,
145 CD45RO, and pSTAT4(pY693) (BD Bioscience, San Jose, CA). Acquisition was set to 20000
146 CD4⁺ events with a LLOQ of 2500[26]. All samples were acquired on a 3 laser/10 color BD
147 FACSCanto. The instrument has been CAP (College of American Pathologists) and CLIA
148 validated for clinical diagnostic studies. The individual antibody concentrations were optimized
149 for maximum separation of the populations[27].

150

151 One capsule of Super 8 HI-Potency Probiotic from Flora containing *L. acidophilus*, *L.*
152 *rhamnosus*, *L. salivarius*, *L. plantarum*, *L. casei*, *B. bifidum* and *B. longum* was resuspended in
153 PBS and a total of 10⁶ cells were added to 10⁶ PBMC in the presence or absence of IL-12
154 neutralizing antibodies (BioRad) and incubated for 18 hours at 37°C. Control samples were
155 stimulated with IL-12 for 2 hours. The experiment was done six times and representative plots
156 are shown. The percentage reduction in pSTAT4 phosphorylation was calculated using the
157 CD45RO⁺/pSTAT4⁺ value as $((\text{IL12AB+lactobacilli})-(\text{unstimulated})) * 100 / ((\text{lactobacilli})-$
158 $(\text{unstimulated}))$

159

160 **Data analysis and modelling.**

161 Data analysis of flow cytometry data was performed using FCS Express software (De Novo
162 software, Glendale, CA). All data comparisons were analyzed as paired, two tailed, two-sample
163 unequal variance using Student's t-test to determine significance. A p-value less than 0.05 was
164 considered significant, * p<0.05, ** p<0.01.

165

166 Protein structure modeling was performed using AlphaFold [28]. The resulting models were
167 aligned and visualized using Chimera[29].

168

169 **Plasmid constructs**

170 Human codon-optimized wild-type IL-12Rb1 and IL-12Rb2 protein sequences were synthesized
171 by MolecularCloud (HG11674-UT and HG10145-UT, respectively) and then cloned into
172 lentiviral plasmid constructs with RFP and GFP reporters, respectively. The overlap extension
173 PCR method was used to generate the mutant IL12Rb1 Q238E protein sequence and clone it into
174 the lentivector. IL-12Rb1 Q238E sequence was then confirmed using sequencing by Eton Bio.
175 Primer sequences are available upon request.

176

177 **Lentivirus production**

178 The lentiviruses pseudotyped with vesicular stomatitis virus G protein envelope were generated
179 with HEK293T cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer's
180 protocol as previously described [30].

181

182 **Engineering primary human T cells and Jurkat cells**

183 Healthy adult blood was obtained from AllCells. Primary CD4 T cells were isolated, activated,
184 transduced to overexpress IL12Rb1 wild-type or mutant, and proliferated as previously described
185 [31]. Total PBMC were activated with antiCD3/anti-CD28 dynabeads (Invitrogen) and expanded
186 in IL-2 (10ng/ml) containing media. To generate IL12Rb1 wild-type or mutant and IL12Rb2
187 overexpressing Jurkat cells, wild-type Jurkats were transduced with the IL-12Rb2 lentiviruses,

188 co-expressing GFP marker, and superinfected with IL-12Rb1 wild-type or IL-12Rb1 Q238E
189 lentiviruses, co-expressing RFP marker, at MOI=3. The infection levels were determined by GFP
190 or RFP expression using flow cytometry analysis. Engineered Jurkat cells were later single-cell
191 cloned with FACS Aria Fusion (BD Biosciences). To further confirm IL-12 receptors
192 overexpression, transduced cells were stained with IL-12Rb1 (R&D) and IL-12Rb2 (Biolegend)
193 antibodies. For phospho-Stat4 staining, total resting or activated PBMCs, engineered primary
194 CD4 T or Jurkat cells were stimulated with different concentrations of IL-12 (R&D) for 90
195 minutes. Cells were collected, stained with fixable viability dye (eBiosciences) and surface
196 markers including IL-12Rb1 (R&D biosystems), CD3, CD4 and CD8 (Biolegend) to identify
197 PBMC populations, washed then fixed with Cytofix buffer (BD) prewarmed to 37°C for 10 min.
198 After spinning down, the cells were permeabilized with ice-cold Phosflow Perm buffer III (BD)
199 on ice for 30 min and were stained with phospho-Stat4 (pY693) antibody (BD) or total Stat4
200 primary antibody followed by anti-rabbit secondary antibody (both from Invitrogen). Stained
201 cells were analyzed on BD Symphony A5 flow cytometer (BD Biosciences). Flow cytometry
202 data was analyzed using FlowJo software.

203

204

205 **Statistical Analyses and Reproducibility**

206 All statistical analyses were performed, and graphs were prepared using GraphPad Prism V9
207 software. Each experiment was performed at least three times and non-parametric t-tests were
208 used for statistical significance analyses.

209

210 **Results**

211 **Identification of a Th1 defect in a family of patients with RCRS.**

212 The patient is a 63-69 year-old Caucasian female with a long-standing history of chronic
213 pansinusitis without polyps, and osteomyelitis of the right maxillary sinus wall. Sinus cultures
214 grew methicillin resistant *S. aureus* and *Klebsiella* species on multiple occasions. Patients
215 underwent multiple sinus surgeries and procedures involving ethmoid, maxillary and frontal
216 sinuses. Sinus surgical pathology results show predominantly neutrophilic infiltrates (Figure 1A).
217 The patient's immune evaluation showed slight hypogammaglobulinemia (400-500 mg/dL
218 range) on multiple occasions along with poor responses to *S. pneumoniae* serotypes (3/14 of the
219 serotypes with protective levels above 1.3 mcg/ml despite multiple boosters with Pneumovax23).
220 Serum IgM, IgA and IgE levels were within normal limits. The patient's B cells expressed
221 normal CD27, IgG, IgA, IgM and IgD, arguing against a primary antibody deficiency disorder.
222 T-cells, including T-cell subsets and NK cells were normal for absolute numbers and
223 percentages. Given the poor response to antibiotic therapies, and persistently borderline low IgG,
224 the patient was started on IgG replacement therapy which resulted in partial clinical
225 improvement of the sinus disease.

226
227 Since the patient's clinical presentation was not fully explained by the low serum IgG and only a
228 partial clinical response to the IgG replacement therapy, whole exome sequencing was
229 performed, which revealed a heterozygous mutation in the *IL12RB1* gene, 712 C>G resulting in
230 the p.Gln238Glu variant. The variance was confirmed by Sanger sequencing in the patient as
231 well as in four of her five children (Figure 1B+1C). The p.Gln238Glu variant is classified as a
232 variant of uncertain significance (VUS) in ClinVar[32]. The structure modeling of the molecular
233 defect maps it to the linker region to the cytokine binding domain (Supplemental figure 1). The

234 mutation did not affect the expression level of IL12Rb1 receptor on the cell surface or the ability
235 of CD4 cells to produce IL-17 or IFN γ in response to general activation by PMA plus ionomycin
236 (Figure 1D and Figure 2). We then hypothesized that it could be possible for the mutated
237 receptor to still form complexes with the IL23R or IL-12R β 2 but not bind IL-12 or IL-23 in a
238 conformation that activates downstream signaling. The patient's RCRS history led us to focus on
239 IL-12/Th1 rather than IL-23/Th17 defects. To assess the potential role of the *IL12R β 1* mutation
240 on IL-12 signaling, we measured IFN γ production by stimulating PBMC from the patient and
241 healthy age matched controls after IL12R β 1 specific stimulation. The expected result for a
242 heterozygous patient would be a reduction rather than abolishing IL-12 signaling. The results
243 show that the percentages of the CD4⁺ T cells that are IFN γ ⁺ after stimulation are 4.6% for the
244 healthy control versus 5.2% for the patient. However, only 0.5% of the patient's CD4⁺ T-cells
245 are IFN γ ^{high} compared to 2.8% in the healthy control (Figure 3).

246

247 To identify the Th1 defect, we measured the phosphorylation of STAT4 in response to IL-12
248 stimulation in CD3⁺/CD4⁺/CD45RO⁺ cells at various time points between 0 and 5 hours. The
249 result for the patient is an average of three samples each collected a month apart. They were
250 compared to a group of age matched healthy controls (n=5) and patients with various well
251 defined immune deficiencies requiring antibody replacement therapy (n=5). Healthy controls
252 showed an increase in percentage of p-STAT4 positive T-helper memory cells after 30 minutes
253 of stimulation with IL-12 which peaked after 60-120 minutes followed by a slow decrease after
254 180 minutes. The patient's p-STAT4 response was significantly blunted at all time points.
255 (Figure 4A and 4B).

256

257 We subsequently tested four of the patient's adult children. The IL-12 induced STAT4
258 phosphorylation showed that the three siblings with the mutation showed a lower peak in STAT4
259 phosphorylation after 60 minutes compared to the sibling without the mutation (Figure 4C). One
260 of the three siblings with the mutation had a history of recurrent sinusitis and pneumonia.

261

262 **Transfection Experiments to show the impact of Q2883 mutation on primary T cells.**

263 The modeling of the IL12 receptor did not show any difference in the folding of the receptor
264 between the wild type and the p.Gln238Glu variant (Supplemental Figure 1). To determine
265 whether the mutated IL12 receptor is the cause of the defective STAT4 phosphorylation, we first
266 engineered primary CD4⁺ T cells to overexpress the WT or the mutated IL-12Rb1 (Supplemental
267 Figure 2). We saw no difference in the phosphorylation of STAT4 on IL12 stimulation in these
268 primary CD4⁺ T cells when compared those engineered to express wild-type or mutant IL12Rb1.
269 (Supplemental Figure 3). A significant challenge posed by this system is the mosaicism of the
270 cells harboring the mutant receptors, as they also express normal IL12b1 receptors constitutively.
271 Consequently, IL12 may exhibit a preferential activation of the normal receptor, complicating
272 the functional analysis of the mutant variant. To address this issue, we utilized Jurkat cells,
273 which are deficient in IL12b1. Jurkat cells also express high levels of STAT4 constitutively
274 (Figure 5). Thus, we genetically expressed either the wild-type (WT) or the mutant variant of
275 this receptor in Jurkat cells along with the IL-12Rb2, which is required to form heterodimer with
276 IL-12Rb1 for the signaling via IL-12 (Supplemental Figure 4). In these genetically engineered
277 Jurkat cells, upon stimulation with IL-12 we could detect phosphorylation of STAT4, but not
278 wild type Jurkat line, suggesting efficient reconstitution of the receptor complex for this
279 signaling pathway. Overexpression of IL12Rb1 and IL12Rb2 genes also led to high level

280 expression of these receptors on cell surface of the Jurkat cells and was comparable between the
281 mutant and the WT IL-12Rb1 expressing cells (Figure 6A). Upon stimulation of with IL-12,
282 there was no difference for STAT4 phosphorylation between the Jurkat cells expressing WT or
283 the mutant IL12Rb1 (Figure 6B). As we couldn't establish a conclusive link between the
284 patient's mutation and the signaling defect, we opted to examine a larger number of individual
285 clones.

286
287 We therefore asked if there factors other than IL-12R and STAT4 expression could potentially
288 affect the IL-12 signaling. We reasoned such differences could only be detected at single cell
289 clone levels. Accordingly, Jurkat cells engineered to overexpress WT IL-12Rb2 and WT IL-
290 12Rb1 were single cell sorted based on GFP and RFP expression, single cell clones were
291 expanded for 3-4 weeks and pStat4 levels in different clones were measured after IL-12
292 stimulation. Remarkably, while the IL-12 receptor levels were high and comparable among all
293 clones (over 40 clones were analyzed), pSTAT4 levels were widely different between clones
294 stimulated with IL-12 (Figure 7A). These results suggest that yet to be determined intermediary
295 factors between the receptor and STAT phosphorylation, for example kinases such as Tyk2 or
296 Jak2, may influence the efficiency, which could explain the results observed in the family
297 reported in this article (Figure 7B).

298

299

300 **Validation of the pSTAT4 assay**

301 In the context of CRS, dysbiosis in the upper airway microbiome can influence IL12 signaling.
302 For example, mucin-fermenting bacteria in CRS may degrade and ferment mucins, altering the

303 airway environment and promoting inflammation that could disrupt IL12 signaling [33].

304 Additionally, elevated short chain fatty acid levels in CRS mucus may also impact this pathway
305 [34]. This suggests that apart from genetic factors, extrinsic factors, such as microbial
306 imbalances could contribute to IL12 signaling defects in CRS.

307 To test this hypothesis, we next sought to test a larger cohort of patients with RCRS, to see if the
308 variability we see in the pSTAT4 levels in the clones is reflected between patients. The
309 phosphorylation of STAT4 after IL-12 stimulation allows for a functional readout of the
310 signaling regardless of the location of the genetic variations in the IL-12/IFN γ axis or molecules
311 that influence it, which can vary between patients. To do this, we first validated the assay so that
312 the results are consistent and that it can be included in the clinical workup of patients with CRS.
313 The previously published pSTAT4 assay, used to study IL-12 receptor mutations, relied on the
314 hypothetical approach of maximizing IL-12 receptor expression by inducing blastogenesis using
315 PHA, a process that typically takes 5-7 days. The blasts are then subsequently stimulated with
316 IL-12 [35–37]. This approach can be employed in a research setting to demonstrate that IL-12
317 receptor mutations can disrupt IL-12 signaling. However, it is not well-suited for routine clinical
318 testing due to the challenges associated with validating a multistep process that involves
319 numerous variables in blastogenesis. Additionally, blasts may not accurately reflect a
320 physiological response in vivo, as the majority of circulating cells are not in a continuous
321 activated state. Furthermore, our findings indicate that the expression of T cell surface IL-12
322 receptors remains unchanged between resting T cells and blasts. (Supplemental Figure 5). The
323 pSTAT4 assay performed on resting primary T cells and validated under CAP/CLIA utilizes
324 whole blood within 24 hours [26]. The assay measures STAT4 phosphorylation at multiple time
325 points, extending up to 2 hours, and can be finalized within 5 hours. It exhibits high

326 reproducibility and is accompanied by reference ranges, enabling us to assess a patient's
327 condition without the need to include a group of healthy controls.

328

329 **pSTAT4 to screen CRS for prolonged surgical recovery.**

330 In addition to the results from our Jurkat clones showing variability in STAT4 phosphorylation,
331 the published reports on T cell defects in up to 56% of RCRS patients supported our approach to
332 screen a larger cohort of RCRS patients [38]. To assess the clinical relevance of our finding in
333 the larger RCRS population, we used the IL-12 induced pSTAT4 as a screening assay in 147
334 RCRS patients requiring surgery (Figure 8 and Supplemental Figure 6). These RCRS patients
335 presented with infections of *Klebsiella*, *Staphylococcus*, *Serratia* and *Burkholderia* species
336 isolated from sinus cultures, and had history of multiple sinus procedures, no polyps. These
337 patient's nasal mucosa showed areas of inflammation, often with one side or another showing
338 much worse disease, rather than widespread inflammation. Chronic inflammatory infiltrates were
339 common to all RCRS patients' tissue specimens, performed as a part of their post-surgical
340 specimen processing. Bad surgical outcome was defined as requiring more than two courses of
341 antibiotic therapy within the first 6 months after surgery. Low STAT4 phosphorylation
342 correlated with prolonged surgical recovery of lengthy healing process as well as persistence of
343 the sinus infections. None of the individuals in the control group or the patients with a good
344 surgical outcome had a pSTAT4 value below 5% whereas most of the patients with poor surgical
345 outcome had a value below 5%. To test if a soluble factor (i.e. anti-cytokine antibody) was
346 responsible for low STAT4 phosphorylation, we performed the experiments on health subjects
347 CD4 T cells using RCRS patient serum. Serum of RCRS patients with low pSTAT4 did not

348 result in healthy patients' cells down-regulating STAT4 phosphorylation in response to IL-12
349 stimulation (Supplemental figure 7).

350

351 **Effect of Lactobacilli on STAT4 phosphorylation in-vitro and in vivo**

352 In our follow-up experiments, we explored the potential impact of lactobacilli on pSTAT4
353 phosphorylation. This investigation was prompted by data suggesting that specific lactobacilli
354 strains can trigger IL-12 production in macrophages and by anecdotal observations within our
355 group regarding the potential clinical advantages of probiotics in chronic sinus disease. Our
356 results demonstrated that when PBMCs were exposed to a lactobacilli solution containing *L.*
357 *acidophilus* for 18 hours, STAT4 phosphorylation was induced, even in the absence of
358 exogenous IL-12 supplementation. Intriguingly, when the lactobacilli solution was introduced to
359 PBMCs of patients exhibiting low STAT4 phosphorylation in their CD4 T-cells, there was a
360 notable enhancement in STAT4 phosphorylation. This effect was partially inhibited by
361 neutralizing anti-IL12 antibodies (Figure 9). This suggests that the probiotic's effect can be
362 attributed to IL12 production but contributions from an IL-12 independent pathway could not be
363 ruled out. The phosphorylation of STAT4 by lactobacilli, as well as its inhibition of IL-12,
364 exhibits specificity to both the bacterial strain and the host (Supplemental Figure 8).

365

366 In light of these findings, we conducted a retrospective review of medical records for 25 CRS
367 patients who were administered *Latilactobacillus sakei*, a strain reported for its ability to induce
368 exceptionally high IL-12 levels [39]. We gauged the patients' response to the probiotic by
369 correlating the number of postoperative office visits and change in pSTAT4 levels pre-and post-
370 probiotic use in a 1-year period. The results present pSTAT4 levels as a percentage change, and

371 the outpatient data reflect the difference in visit frequency. Our analysis underscored a positive
372 correlation between the frequency of patients' post-surgical visits and the pSTAT4
373 phosphorylation in their CD4 T cells (Figure 10).

374

375 **Discussion**

376 CRS remains a nuanced pathology, both in its presentation and underlying etiologies. In this
377 study, we started out with exploring a VUS in the IL-12 receptor beta 1 of an RCRS patient.
378 Despite the patient's receptor expressing normally on peripheral blood T-helper cells, our
379 discoveries highlighted a compromised IL-12 signaling. Even though there is a correlation in the
380 patient's family between individuals with the mutation and low pSTAT4 response we were
381 unable to show an effect of the mutation in computational structural simulation models or by *in*
382 *vitro* transfection experiments.

383

384 Broadening our scope, we undertook a validated pSTAT4 assay across an expansive cohort of
385 RCRS patients. The outcome was illuminating; diminished STAT4 phosphorylation in CD4 T-
386 cells heralded poor post-surgical recoveries. While this finding seemed to be a validation of prior
387 research emphasizing T-cells' pivotal roles in RCRS, it also accentuated a conspicuous gap in
388 clinical practice: the lack of routine cellular immunity assessments of these patients, despite their
389 potential diagnostic importance. The common practice of immune evaluation of CRS involves
390 measuring serum quantitative antibody levels, which, more often than not, provide inconclusive
391 results [25,40,41]. As this research underscores specific defects in T cell function and offers a
392 clinically validated diagnostic tool, we anticipate a paradigm shift towards more tailored
393 therapeutic approaches for RCRS. However, unveiling the exact mechanics behind impaired IL-

394 12-mediated STAT4 phosphorylation remains to be determined, the deciphering of which could
395 usher in therapeutic breakthroughs.

396
397 Another riveting aspect of our study revolves around the interplay between *Lactobacillus* species
398 and the immune system. With their presence predominantly in the human gut, *Lactobacillus*
399 species' interactions with macrophages can influence cytokine profiles, including IL-12 [42]. We
400 confirmed this in our *in vitro* analysis using neutralizing IL-12 antibodies which reduced the
401 effect of *L. acidophilus*. Furthermore, the *L. acidophilus* was able to induce STAT4
402 phosphorylation in the absence of any exogenous IL-12. But not all *Lactobacilli* are created
403 equal. Potentially, strain-specific variability can exist in their potency to modulate IL-12,
404 potentially attributed to differences in their cell walls [43]. This study further delves into this
405 variability, reinforcing the importance of strategic *Lactobacillus* selection in potential therapeutic
406 endeavors. The precise mechanism of *Lactobacillus* stimulation of T cells is not entirely known
407 and our data shows both IL-12 independent as well as dependent phosphorylation of STAT4.
408 The STAT4 phosphorylation we observe in Figure 9A is lower than what we see when saturating
409 the blood sample with IL-12, but it is likely to be adequate, *in vivo*, to activate and poise the Th-1
410 cells in patients with low pSTAT4 response and lead to improved clinical outcomes in
411 postsurgical RCRS patients.

412
413 Our *Lactobacillus* data provide important insights into the inconsistent findings in the literature
414 concerning the clinical effects of *Lactobacillus* on Chronic Rhinosinusitis (CRS) outcomes. The
415 data highlight two key factors: Firstly, the specific strains of probiotics and individual host
416 characteristics significantly influence STAT4 phosphorylation. This effect's strength and its IL-

417 12 dependence vary, as evidenced by the inhibition assays presented in Figure 5 and
418 Supplementary Figure 8. Future research should identify the probiotic structural components
419 responsible for these effects. Secondly, the choice of clinical endpoints is crucial. Given that
420 STAT4 phosphorylation is pivotal in regulating Th1 cell responses, our research prioritized post-
421 surgical wound healing rather than improvements in clinical symptoms or reductions in sinus
422 infection rates. [44–46]. The process of wound healing begins with an immediate inflammatory
423 response, seeing an influx of various cellular actors. Th1 cells, through their influence on
424 macrophages and fibroblasts and their production of IFN- γ , impact collagen synthesis, the
425 bedrock of tissue repair [47]. However, maintaining a balance in Th1 activity is paramount. An
426 overwhelming or inadequate Th1 response can either prolong inflammation or inadequately
427 support the initial healing phases, respectively. As such, understanding Th1 activity, primarily
428 via STAT4 phosphorylation, provides invaluable insights into predicting and optimizing surgical
429 outcomes. Furthermore, the microbiota can induce an adaptive immune response that can couple
430 antimicrobial function with tissue repair and wound healing [48]. It has been shown that non-
431 classical MHC class I molecules, an evolutionarily ancient arm of the immune system, can
432 promote immunity to the microbiota, such as *Lactobacillus*, and subsequently affect cytokine
433 signaling, including IL-12 [49]. To enhance our understanding of Recurrent Chronic
434 Rhinosinusitis (RCRS), it is crucial to conduct prospective studies focusing on the IL-12
435 pathway. Investigating its specific functions could provide insights into its dual role in infection
436 control and inflammation regulation.

437

438 A limitation of our study is that it was not designed prospectively, and it depended on the
439 analysis of retrospective review of patient charts. To further corroborate our clinical findings,
440 future studies should be prospective, randomized, and placebo controlled.

441
442 Finally, our research underscores the critical role of Laboratory Developed Tests (LDTs) in
443 enhancing clinical diagnostics and patient care, with a special focus on the pSTAT4 assay as an
444 example. Unlike test kits cleared by the Food and Drug Administration (FDA), LDTs bridge the
445 gap in diagnosing complex or rare conditions. Their ability to rapidly integrate cutting-edge
446 diagnostic methods makes them an essential tool in the dynamic healthcare environment,
447 especially when leveraged by skilled clinicians. The pSTAT4 test, in particular, has shown
448 promise as a predictor of outcomes following sinus surgeries, potentially revolutionizing the
449 management strategies for RCRS. Given these findings, there is a compelling case for the
450 broader adoption of LDTs like pSTAT4 in clinical settings and a call for more research to further
451 establish their utility and impact on patient care trajectories.

452

453 **Conclusion**

454 As our grasp of RCRS and its complex underlying mechanisms grows, evaluating T-cell defects
455 using the STAT4 phosphorylation assay described in this study emerges as a particularly
456 promising avenue. These innovative diagnostic and therapeutic strategies that evolve from them,
457 have the potential to transform our management of CRS. When utilized with precision, they offer
458 a path toward alleviating the substantial strain that CRS places on healthcare systems.

459

460 **References**

- 461 [1] Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways.
462 *Immunol Rev* 2005;203:38–47. <https://doi.org/10.1111/j.0105-2896.2005.00227.x>.
- 463 [2] Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification
464 of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human
465 lymphocytes. *J Exp Med* 1989;170:827–45. <https://doi.org/10.1084/jem.170.3.827>.
- 466 [3] Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection,
467 inflammation and autoimmune disorders. *Inflamm Allergy Drug Targets* 2009;8:40–52.
468 <https://doi.org/10.2174/187152809787582507>.
- 469 [4] Malmgaard L. Induction and regulation of IFNs during viral infections. *J Interferon Cytokine Res*
470 2004;24:439–54. <https://doi.org/10.1089/1079990041689665>.
- 471 [5] Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, et al. STAT4 serine
472 phosphorylation is critical for IL-12-induced IFN- γ production but not for cell proliferation. *Proc*
473 *Natl Acad Sci USA* 2002;99:12281–6. <https://doi.org/10.1073/pnas.182618999>.
- 474 [6] Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu C-Y, et al. A functional interleukin 12
475 receptor complex is composed of two β -type cytokine receptor subunits. *Proc Natl Acad Sci USA*
476 1996;93:14002–7. <https://doi.org/10.1073/pnas.93.24.14002>.
- 477 [7] De Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al.
478 Revisiting Human IL-12R β 1 Deficiency: A Survey of 141 Patients From 30 Countries. *Medicine*
479 2010;89:381–402. <https://doi.org/10.1097/MD.0b013e3181fdd832>.
- 480 [8] Van De Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin
481 A, et al. IL-12R β 1 Deficiency: Mutation Update and Description of the *IL12RB1* Variation
482 Database. *Human Mutation* 2013;34:1329–39. <https://doi.org/10.1002/humu.22380>.
- 483 [9] Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, et al. Low Penetrance,
484 Broad Resistance, and Favorable Outcome of Interleukin 12 Receptor β 1 Deficiency. *The Journal of*
485 *Experimental Medicine* 2003;197:527–35. <https://doi.org/10.1084/jem.20021769>.
- 486 [10] Rosain J, Oleaga-Quintas C, Deswarte C, Verdin H, Marot S, Syridou G, et al. A Variety of Alu-
487 Mediated Copy Number Variations Can Underlie IL-12R β 1 Deficiency. *J Clin Immunol*
488 2018;38:617–27. <https://doi.org/10.1007/s10875-018-0527-6>.
- 489 [11] Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L. Mendelian susceptibility to mycobacterial
490 disease: Genetic, immunological, and clinical features of inborn errors of IFN- γ immunity. *Seminars*
491 *in Immunology* 2014;26:454–70. <https://doi.org/10.1016/j.smim.2014.09.008>.
- 492 [12] Cleary AM, Tu W, Enright A, Giffon T, Dewaal-Malefy R, Gutierrez K, et al. Impaired
493 Accumulation and Function of Memory CD4 T Cells in Human IL-12 Receptor β 1 Deficiency. *The*
494 *Journal of Immunology* 2003;170:597–603. <https://doi.org/10.4049/jimmunol.170.1.597>.
- 495 [13] Jacobson NG, Szabo SJ, Güler ML, Gorham JD, Murphy KM. Regulation of interleukin-12
496 signalling during T helper phenotype development. *Adv Exp Med Biol* 1996;409:61–73.
497 https://doi.org/10.1007/978-1-4615-5855-2_9.
- 498 [14] Smith A, Buchinsky FJ, Post JC. Eradicating chronic ear, nose, and throat infections: a
499 systematically conducted literature review of advances in biofilm treatment. *Otolaryngol Head Neck*
500 *Surg* 2011;144:338–47. <https://doi.org/10.1177/0194599810391620>.
- 501 [15] Lee VS. Topical Irrigations for Chronic Rhinosinusitis. *Immunol Allergy Clin North Am*
502 2020;40:317–28. <https://doi.org/10.1016/j.iac.2019.12.014>.
- 503 [16] Czibulka A. Probiotics for Otolaryngologic Disorders. *Otolaryngol Clin North Am* 2022;55:939–46.
504 <https://doi.org/10.1016/j.otc.2022.06.003>.
- 505 [17] Psaltis AJ, Mackenzie BW, Cope EK, Ramakrishnan VR. Unraveling the role of the microbiome in
506 chronic rhinosinusitis. *J Allergy Clin Immunol* 2022;149:1513–21.
507 <https://doi.org/10.1016/j.jaci.2022.02.022>.
- 508 [18] Bourdillon AT, Edwards HA. Review of probiotic use in otolaryngology. *Am J Otolaryngol*
509 2021;42:102883. <https://doi.org/10.1016/j.amjoto.2020.102883>.
- 510 [19] Cervin AU. The Potential for Topical Probiotic Treatment of Chronic Rhinosinusitis, a Personal
511 Perspective. *Front Cell Infect Microbiol* 2017;7:530. <https://doi.org/10.3389/fcimb.2017.00530>.

- 512 [20] Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal
513 pouch-anal anastomosis for chronic ulcerative colitis. *Cochrane Database Syst Rev*
514 2010;CD001176. <https://doi.org/10.1002/14651858.CD001176.pub2>.
- 515 [21] Yazdi MH, Soltan Dallal MM, Hassan ZM, Holakuyee M, Agha Amiri S, Abolhassani M, et al.
516 Oral administration of *Lactobacillus acidophilus* induces IL-12 production in spleen cell culture of
517 BALB/c mice bearing transplanted breast tumour. *Br J Nutr* 2010;104:227–32.
518 <https://doi.org/10.1017/S0007114510000516>.
- 519 [22] Shida K, Kiyoshima-Shibata J, Kaji R, Nagaoka M, Nanno M. Peptidoglycan from lactobacilli
520 inhibits interleukin-12 production by macrophages induced by *Lactobacillus casei* through Toll-like
521 receptor 2-dependent and independent mechanisms. *Immunology* 2009;128:e858-869.
522 <https://doi.org/10.1111/j.1365-2567.2009.03095.x>.
- 523 [23] Shida K, Kiyoshima-Shibata J, Nagaoka M, Watanabe K, Nanno M. Induction of interleukin-12 by
524 *Lactobacillus* strains having a rigid cell wall resistant to intracellular digestion. *J Dairy Sci*
525 2006;89:3306–17. [https://doi.org/10.3168/jds.S0022-0302\(06\)72367-0](https://doi.org/10.3168/jds.S0022-0302(06)72367-0).
- 526 [24] Desrosiers M. Refractory chronic rhinosinusitis: pathophysiology and management of chronic
527 rhinosinusitis persisting after endoscopic sinus surgery. *Curr Allergy Asthma Rep* 2004;4:200–7.
528 <https://doi.org/10.1007/s11882-004-0027-z>.
- 529 [25] Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al.
530 Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg* 2015;152:S1–39.
531 <https://doi.org/10.1177/0194599815572097>.
- 532 [26] PSTAT Validation — Amerimmune n.d. <https://www.amerimmune.com/pstat-validation> (accessed
533 October 17, 2023).
- 534 [27] Ryherd M, Plassmeyer M, Alexander C, Eugenio I, Kleschenko Y, Badger A, et al. Improved panels
535 for clinical immune phenotyping: Utilization of the violet laser. *Cytometry B Clin Cytom*
536 2018;94:671–9. <https://doi.org/10.1002/cyto.b.21532>.
- 537 [28] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein
538 structure prediction with AlphaFold. *Nature* 2021;596:583–9. [https://doi.org/10.1038/s41586-021-](https://doi.org/10.1038/s41586-021-03819-2)
539 03819-2.
- 540 [29] Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF CHIMERA²:
541 Structure visualization for researchers, educators, and developers. *Protein Science* 2021;30:70–82.
542 <https://doi.org/10.1002/pro.3943>.
- 543 [30] Dogan M, Kozhaya L, Placek L, Karabacak F, Yigit M, Unutmaz D. Targeting SARS-CoV-2
544 infection through CAR-T-like bispecific T cell engagers incorporating ACE2. *Clin & Trans*
545 *Imm* 2022;11:e1421. <https://doi.org/10.1002/cti2.1421>.
- 546 [31] Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, et al. Engineering Human MAIT Cells
547 with Chimeric Antigen Receptors for Cancer Immunotherapy. *The Journal of Immunology*
548 2022;209:1523–31. <https://doi.org/10.4049/jimmunol.2100856>.
- 549 [32] VCV000328593.9 - ClinVar - NCBI n.d.
550 https://www.ncbi.nlm.nih.gov/clinvar/variation/328593/?new_evidence=true (accessed October 1,
551 2023).
- 552 [33] Cho D-Y, Hunter RC, Ramakrishnan VR. The Microbiome and Chronic Rhinosinusitis. *Immunol*
553 *Allergy Clin North Am* 2020;40:251–63. <https://doi.org/10.1016/j.iac.2019.12.009>.
- 554 [34] Säemann MD, Parolini O, Böhmig GA, Kelemen P, Krieger P-M, Neumüller J, et al. Bacterial
555 metabolite interference with maturation of human monocyte-derived dendritic cells. *J Leukoc Biol*
556 2002;71:238–46.
- 557 [35] Sogkas G, Atschekzei F, Schacht V, Von Falck C, Jablonka A, Jacobs R, et al. First Association of
558 Interleukin 12 Receptor Beta 1 Deficiency with Sjögren’s Syndrome. *Front Immunol* 2017;8:885.
559 <https://doi.org/10.3389/fimmu.2017.00885>.
- 560 [36] Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of Intracellular Phosphorylated STAT-4
561 by Flow Cytometry. *Clinical Immunology* 2001;100:270–6. <https://doi.org/10.1006/clim.2001.5078>.

- 562 [37] Fieschi C. A novel form of complete IL-12/IL-23 receptor 1 deficiency with cell surface-expressed
563 nonfunctional receptors. *Blood* 2004;104:2095–101. <https://doi.org/10.1182/blood-2004-02-0584>.
- 564 [38] Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. *Journal of Allergy
565 and Clinical Immunology* 2013;131:1263-1264.e6. <https://doi.org/10.1016/j.jaci.2013.02.020>.
- 566 [39] Chung K-S, Choi JW, Shin J-S, Kim S-Y, Han H-S, Kim S-Y, et al. Strain-Specific Identification
567 and In Vivo Immunomodulatory Activity of Heat-Killed *Lactobacillus sakei* K040706. *Foods*
568 2021;10:3034. <https://doi.org/10.3390/foods10123034>.
- 569 [40] Chiarella SE, Grammer LC. Immune deficiency in chronic rhinosinusitis: screening and treatment.
570 *Expert Rev Clin Immunol* 2017;13:117–23. <https://doi.org/10.1080/1744666X.2016.1216790>.
- 571 [41] Alpan O, Loizou D, Santos I, Ness B, Plandowski J. Impact of immune work-up on outcomes and
572 the cost of care in patients with Chronic Rhinosinusitis. *Allergy* 2019;74:1802–5.
573 <https://doi.org/10.1111/all.13793>.
- 574 [42] Quinteiro-Filho WM, Brisbin JT, Hodgins DC, Sharif S. *Lactobacillus* and *Lactobacillus* cell-free
575 culture supernatants modulate chicken macrophage activities. *Res Vet Sci* 2015;103:170–5.
576 <https://doi.org/10.1016/j.rvsc.2015.10.005>.
- 577 [43] Rocha-Ramírez LM, Pérez-Solano RA, Castañón-Alonso SL, Moreno Guerrero SS, Ramírez
578 Pacheco A, García Garibay M, et al. Probiotic *Lactobacillus* Strains Stimulate the Inflammatory
579 Response and Activate Human Macrophages. *J Immunol Res* 2017;2017:4607491.
580 <https://doi.org/10.1155/2017/4607491>.
- 581 [44] Ellis S, Lin EJ, Tartar D. Immunology of Wound Healing. *Curr Derm Rep* 2018;7:350–8.
582 <https://doi.org/10.1007/s13671-018-0234-9>.
- 583 [45] Eming SA, Krieg T, Davidson JM. Inflammation in Wound Repair: Molecular and Cellular
584 Mechanisms. *Journal of Investigative Dermatology* 2007;127:514–25.
585 <https://doi.org/10.1038/sj.jid.5700701>.
- 586 [46] Raziyeva K, Kim Y, Zharkinbekov Z, Kassymbek K, Jimi S, Saparov A. Immunology of Acute and
587 Chronic Wound Healing. *Biomolecules* 2021;11:700. <https://doi.org/10.3390/biom11050700>.
- 588 [47] Dumitru C, Kabat AM, Maloy KJ. Metabolic Adaptations of CD4+ T Cells in Inflammatory
589 Disease. *Front Immunol* 2018;9:540. <https://doi.org/10.3389/fimmu.2018.00540>.
- 590 [48] Linehan JL, Harrison OJ, Han S-J, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et al. Non-classical
591 Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair. *Cell* 2018;172:784-
592 796.e18. <https://doi.org/10.1016/j.cell.2017.12.033>.
- 593 [49] Vemuri R, Gundamaraju R, Shinde T, Perera AP, Basheer W, Southam B, et al. *Lactobacillus*
594 *acidophilus* DDS-1 Modulates Intestinal-Specific Microbiota, Short-Chain Fatty Acid and
595 Immunological Profiles in Aging Mice. *Nutrients* 2019;11:1297.
596 <https://doi.org/10.3390/nu11061297>.
- 597

598

599 **Figure legends:**

600 **Figure 1**

601 Characterizing of the patient. A) Endoscopic photograph of the patient's sinus. B) Sanger

602 sequencing of the *IL12Rb1* gene. C) Pedigree of the patient and her family. D) CD212

603 (IL12Rβ1) expression on CD4 and CD20 lymphocytes.

604

605 **Figure 2**

606 Stimulation of PBMC with PMA and ionomycin. The percentages of CD3⁺/CD4⁺ lymphocytes
607 that produces IL-17 (normal range 0.2%-2.2%) and IFN γ (normal range 3-30%) were determined
608 by flow cytometry.

609

610 **Figure 3**

611 The mutation affects IL-12 signaling. PBMC stimulated with IL-12, IL-18, IL-2 and
612 CD3&CD28 beads. The IFN γ production were measured in CD3⁺/CD4⁺ lymphocytes. The
613 experiment was repeated three times. Representative plots are shown.

614

615 **Figure 4**

616 STAT4 phosphorylation in response to IL-12 stimulation. A) representative plots. B) Results
617 from the patient, healthy controls and CVID patients. C) Four of the patient's children. "+"
618 indicates wt allele and "-" indicates the mutation.

619

620 **Figure 5**

621 Effect of IL12R β 1 expression on IL-12 induced STAT4 phosphorylation in Jurkat cells.
622 Histograms overlay representing pStat4 after stimulation of wild type or engineered Jurkat cells
623 with wt IL12R β 2, wt IL12R β 1 or both receptors.

624

625 **Figure 6**

626 IL12Rb1 and IL12Rb2 engineered Jurkat cells. A) Expression analyzed by flow cytometry of
627 IL12Rb2 and IL12Rb1. B) Comparison of percent phosphorylated STAT4 expression in
628 engineered Jurkat cells expressing wild-type or mutant IL12Rb1 with or without IL12Rb2.

629

630 **Figure 7**

631 STAT4 phosphorylation in Jurkat clones expressing different levels of IL-12Rb1. A) STAT4
632 phosphorylation after IL-12 stimulation. B) IL12Rb1 expression levels.

633

634 **Figure 8**

635 Percent pSTAT4 positive cells after IL-12 stimulation of whole blood from CRS patients and
636 healthy controls.

637

638 **Figure 9**

639 *In vitro* effects of lactobacilli on STAT4 phosphorylation. A) The percentage of
640 pSTAT4/CD45RO cells for the different conditions indicated in the figure. B) Effect of IL-12
641 neutralizing antibodies on lactobacilli induced STAT4 phosphorylated.

642

643 **Figure 10**

644 Lactobacilli in post-surgery setting. Patient data on the total number of outpatient visits for one
645 year following surgery and pSTAT4 levels before and approximately six months after *L. sakei*
646 treatments.


647

Figure 1


A



B



C



D




Figure 2




Figure 3






Figure 4

A



B



C




Figure 5





Figure 6

A



B





Figure 7

A



B




Figure 8





Figure 9



B Reduction in lactobacilli induced STAT4 phosphorylation by α IL-12




Figure 10

